Kamada (KMDA) has released an update.
Kamada Ltd. has expanded its plasma collection operations with a new center in Houston, Texas, expected to annually collect around 50,000 liters of plasma and contribute $8 to $10 million in revenue at full capacity. This center will focus on both normal source plasma and specialized types like Anti-Rabies and Anti-D, aiming to be one of the largest specialty plasma collection sites in the U.S. Additionally, the company is constructing a third center in San Antonio, slated to open in the first half of 2025.
For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.
